Pipeline by indication
NETRIS Pharma is conducting a large Clinical Development Plan with its lead asset NP137. A pipeline of new products targeting other ligands is also in construction.
Study
| Program Target | Indication | Discovery | IND Enabling | Phase I | Phase II | Late-Stage Development |
|---|---|---|---|---|---|---|
|
GyNET, NCT04652076
NP137 + Pembro(*)/Carbotaxol
|
• Endometrial cancer |
|||||
|
ImmunoNET NCT05605496
NP137 + Approved Immune Checkpoint
|
• NSLCC (**) |
|||||
|
Liver-NET1 NCT05546879
NP137 + Atezo-Bev
|
HCC |
|||||
|
LAP-NET1 NCT05546853
NP137 + Folfirinox
|
Locally Advanced PDAC |
|||||
|
LAP-NET1 NCT06203821
NP137 + Folfirinox
|
Resectable PDAC |
|||||
|
NP137P
|
Endometriosis |
|||||
|
NP137R
|
Netrin-1 expressing cancer (radiotherapy) |
|||||
|
NP800
Undisclosed target
|
Glioblastoma |
(*) In combination with Pembrolizumab, provided through a clinical trial collaboration and supply agreement with Merck & Co. Inc., Kenilworth, NJ, USA.
Supported by MSD :
(**) Indications :
- NSCLC : Non-Small Cell Lung Cancer
- HNSCC : Head and Neck Squamous Cell Carcinoma
- PDAC : Pancreatic Ductal Adenocarcinoma
- HCC : Hepatocellular Carcinoma.
Clinical Development
NETRIS Pharma focuses NP137 development on tumor types where the Epithelial to Mesenchymal Transition (EMT) is a central mechanism of diffusion and resistance to treatment. Several clinical trials are well underway to demonstrate the ability of NP137 to overcome resistance, delay tumor progression and extend overall survival for patients. Through its long-term collaboration with the Leon Bérard Comprehensive Cancer Center, NETRIS Pharma accesses a unique set of multidisciplinary technological platforms to conduct ambitious ancillary research programs to identify relevant biomarkers and better characterize patients who shall most likely benefit from the treatment.
